At 18.1% CAGR, North America Blood Collection Tubes for Liquid Biopsy Market is Projected to be Worth US$ 1,68,467.30 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the North America blood collection tubes for liquid biopsy market was valued at US$ 44,385.94 million in 2023 and is expected to reach US$ 1,68,467.30 million by 2031, registering a CAGR of 18.1% from 2023 to 2031. Technological advancements in liquid biopsy and advantages of liquid biopsy over other diagnostic testing techniques are among the critical factors attributed to drive the North America blood collection tubes for liquid biopsy market growth.

Liquid biopsy has revolutionized the way cancer disease states are detected and monitored. Circulating tumor cell (CTC) tubes, intracellular RNA tubes, circulating cell-free DNA (ccfDNA) tubes, cell-free RNA (cfRNA) tubes, genomic DNA (gDNA) tubes, and more advanced blood collecting tubes are available for liquid biopsy. The ccfDNAs, cfRNAs, and extracellular vehicles (EVs, also known as exosomes) are widely used due to which they are gaining considerable attention in cancer diagnosis. Disease-specific exosome or cfRNA analyses require draw-time concentrations of these analytes preserved in collected samples. Major market players focus on introducing new technologically advanced products in the market. In November 2023, Illumina, Inc., launched TruSight Oncology 500 ctDNA v2, a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not feasible; the assay is also performed to complement tissue-based testing. In February 2024, Delfi Diagnostics, in collaboration with Immunocore Holdings plc, launched a new cancer monitoring test to examine blood for broken pieces of tumor DNA to explore its use in the detection of multiple malignancies. The DELFI-TF assay delivers a genome-wide measure of the proportion of cfDNA that is derived from a tumor, and it is highly correlated with the mutant allele fraction that is used to evaluate treatment response and resistance to immunotherapies in patients suffering from advanced-stage cancer conditions. Thus, technological advancements in liquid biopsies for the detection of cancer are expected to introduce new growth trends in the North America blood collection tubes for liquid biopsy market in the coming years.

On the contrary, lack of skilled professionals hampers the growth of North America blood collection tubes for liquid biopsy market.

By product, the North America blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, Intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held 32.0% share of North America blood collection tubes for liquid biopsy market share in 2023, amassing US$ 14,212.01 million. It is projected to garner US$ 55,364.14 million by 2031 to register 18.5% CAGR during 2023–2031.

In terms of material, the North America blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held 65.1% share of North America blood collection tubes for liquid biopsy market share in 2023, amassing US$ 28,874.32 million. It is projected to garner US$ 1,12,102.34 million by 2031 to register 18.5% CAGR during 2023–2031.

By application, the North America blood collection tubes for liquid biopsy market is segmented into in-vitro diagnostics (IVD) and Research. The in-vitro diagnostics (IVD) segment held 67.9% share of North America blood collection tubes for liquid biopsy market share in 2023, amassing US$ 30,141.37 million. It is projected to garner US$ 1,18,278.83 million by 2031 to register 18.6% CAGR during 2023–2031.

Based on end use, the North America blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held 33.7% share of North America blood collection tubes for liquid biopsy market share in 2023, amassing US$ 14,963.20 million. It is projected to garner US$ 59,386.92 million by 2031 to register 18.8% CAGR during 2023–2031.

Based on country, the North America blood collection tubes for liquid biopsy market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 90.7% share of North America blood collection tubes for liquid biopsy market in 2023. It was assessed at US$ 40,244.73 million in 2023 and is likely to hit US$ 1,52,974.79 million by 2031, registering a CAGR of 18.2% during 2023–2031.

Key players operating in the North America blood collection tubes for liquid biopsy market are Apostle Sciences; Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation, among others.

• In November 2022: Exact Science Corporation announced a new venture Baltimore, Maryland.-based Haystack Oncology, recently raised $56 million in funding led by New York-based investment firm Catalio Capital Management. Haystack is developing a blood test that its founders say can detect trace amounts of circulating DNA from solid tumors, which can indicate the presence of cancer and its possible recurrence.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com